AgomAb Therapeutics
PrivateLast Round
IPO Announced
Feb 9, 2026
Est. Valuation
$779.8M
Total Funding Raised
$327M
Company Overview
AgomAb is a biotechnology company specializing in the development of agonistic antibodies aimed at regenerating damaged tissues.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AgomAb Therapeutics Comps
Public and private peers based on sector, stage, and business model.
AgomAb Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO Announced | Feb 9, 2026 | ||||
| Series D | Oct 25, 2024 | ||||
| Series C | Oct 11, 2023 | ||||
| Series B Extension | Jul 13, 2022 | ||||
| Series B | Mar 10, 2021 | ||||
Series A Extension | Oct 10, 2019 |
AgomAb Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B |
| Asabys Partners | Series B Extension, Series D |
| Van Lanschot Kempen | IPO |
| Kohlberg Kravis Roberts | Series C |
| EQT Life Sciences | Series C |
| Andera Partners | Series A Extension, Series B |
| Fidelity Management & Research Company | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2026
Ontunisertib ready for Phase 2b development for Fibrostenosing Crohn’s Disease.
- Feb 9, 2026
$200M raised in IPO round.
AgomAb Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AgomAb Therapeutics's valuation, stock price, and market status.
